IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid TumorsGlobeNewsWire • 01/17/23
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual MeetingGlobeNewsWire • 12/11/22
IGM Biosciences to Present at the Bank of America Biotech SMID Cap ConferenceGlobeNewsWire • 12/01/22
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/22
IGM Biosciences Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/03/22
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's LymphomaBusiness Wire • 11/02/22
Medivir to present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/12/22
Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual MeetingPRNewsWire • 09/08/22
IGM Biosciences Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/22
IGM Biosciences to Present at the 2022 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/10/22
IGM Biosciences Announces First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/22
IGM Biosciences Announces Closing of Global Collaboration Agreement with SanofiGlobeNewsWire • 05/06/22